霉酚酸
异羟肟酸
组蛋白脱乙酰基酶
化学
组蛋白脱乙酰酶抑制剂
霉酚酸酯
药理学
伏立诺他
生物化学
移植
立体化学
生物
组蛋白
医学
内科学
基因
作者
Daniela Ilieva Batovska,Dong Hoon Kim,Shinya Mitsuhashi,Yoon Sun Cho,Ho Jeong Kwon,Makoto Ubukata
摘要
Mycophenolic acid (MPA, 1), an inhibitor of IMP-dehydrogenase (IMPDH) and a latent PPARgamma agonist, is used as an effective immunosuppressant for clinical transplantation and recently entered clinical trials in advanced multiple myeloma patients. On the other hand, suberoylanilide hydroxamic acid (SAHA), a non-specific histone deacetylase (HDAC) inhibitor, has been approved for treating cutaneous T-cell lymphoma. MPA seemed to bear a cap, a linker, and a weak metal-binding site as a latent inhibitor of HDAC. Therefore, the hydroxamic acid derivatives of mycophenolic acid having an effective metal-binding site, mycophenolic hydroxamic acid (MPHA, 2), 7-O-acetyl mycophenolic acid (7-O-Ac MPHA, 3), and 7-O-lauroyl mycophenolic hydroxamic acid (7-O-L MPHA, 4) were designed and synthesized. All these compounds inhibited histone deacetylase with IC50 values of 1, 0.9 and 0.5 microM, and cell proliferation at concentrations of 2, 1.5 and 1 microM, respectively.
科研通智能强力驱动
Strongly Powered by AbleSci AI